Johnson & Johnson

Medically Necessary: Delaying second doses would reshape the vaccine supply chain

vaccine-vial

This is an excerpt from the February 25, 2021 edition of Medically Necessary, a health care supply chain newsletter. Subscribe here.

Good afternoon. Medically Necessary is a newsletter by Matt Blois about the health care supply chain — how we get drugs, devices and medical supplies to health care providers and patients.

Delaying second doses would reshape the vaccine supply chain

The debate: Some scientists argue the U.S. should delay second doses of COVID-19 vaccines and instead give them to...

https://s29755.pcdn.co/news/medically-necessary-delaying-second-doses-would-reshape-the-vaccine-supply-chain

GSCW chat recap: Wengel on strengthening global supply chain through digitalization, integration

Matt Waller and Kathy Wengel discuss key trends in global supply chain

This fireside chat recap is from Day 3 of FreightWaves’ Global Supply Chain Week. Day 3 focuses on food/perishables and consumer packaged goods.

FIRESIDE CHAT TOPIC: Strategic trends in global supply chain 

DETAILS: Key trends emerged in the global supply chain during the COVID-19 pandemic as suppliers, manufacturers and distributors collaborated to ensure critical supplies were distributed all over the world.

SPEAKER: Kathy Wengel is the executive vice president and chief global supply chain...

https://www.freightwaves.com/news/gscw-chat-recap:-wengel-on-strengthening-global-supply-chain-through-digitalization-integration

Global Supply Chain Week Day 3 preview: Food and CPG

Day Three of Global Supply Chain Week is about food and CPG.

John Tyson, chief sustainability officer of Tyson Foods (NYSE: TSN), is scheduled to kick off Day Three of Global Supply Chain Week, Feb. 24. Tyson will discuss sustainability in global supply chain management with Matt Waller, dean of Sam M. Walton College of Business at the University of Arkansas.

FreightWaves’ eight-day, virtual supply chain event will stream live from Feb. 22 through March 3. Feb. 24 focuses on food and consumer packaged goods (CPG) throughout supply chains.

This is not an...

https://www.freightwaves.com/news/global-supply-chain-week-day-3-preview-food-and-cpg

Fauci Underlines the Need for ‘New Variants’ Ready COVID Vaccines

The US has entered a crucial phase in the pandemic where cases are mounting despite vaccinations.

  • Fauci has highlighted Johnson & Johnson vaccine data to stress on the adaptability of new vaccines.
  • Manufacturers and researchers are working to make vaccines adapt to emerging variants.
  • Meanwhile the US lags in sequencing New Variants which is being ramped up by collaboration.
  • At present the experts has suggested treating each case as a new variant.
  • The US covid figures this month is higher than...

https://mfame.guru/fauci-underlines-the-need-for-new-variants-ready-covid-vaccines/

The Daily Dash: DB Schenker’s US plans; Variant’s growth

DB Schenker eyes US trucking market

The Daily Dash is a quick look at what is happening in the freight ecosystem. In today’s edition, DB Schenker, a leading global logistics player, has its eye set on conquering the U.S. Plus, U.S. Xpress’ CEO sees big things coming for its Variant division, and flatbed operator Daseke reports earnings and issues a mixed outlook for 2021.

A new North American player?

After decades operating a major international freight and warehousing business in the U.S., the logistics division of German rail...

https://www.freightwaves.com/news/the-daily-dash-db-schenkers-us-plans-variants-growth

Johnson & Johnson One Shot COVID Vaccine 90% Effective

According to a Mercury News report, early stage trials of Johnson & Johnson’s experimental coronavirus vaccine show it generated an immune response in nearly all volunteers, with minimal side-effects, after a single dose.

The company expects to report details of more advanced trials later this month and is hoping to apply for authorization from the US Food and Drug Administration soon after.

1-2 Doses Found Effective

Researchers who tested the vaccine in a combined Phase 1-2 trial — mostly meant...

https://mfame.guru/johnson-johnson-one-shot-covid-vaccine-90-effective/

Novavax On The Verge of Making History?

The small vaccinemaker that faced an existential threat is slated to receive up to $2 billion from the U.S. government and a nonprofit organization to develop and manufacture a coronavirus vaccine, says an article published in ScienceMag.

A turnover like no one imagined

Eighteen months ago, a small vaccine maker here called Novavax faced an existential threat: delisting by the NASDAQ stock index. On the heels of a second failed vaccine trial in less than 3 years, the firm’s shares had plunged to...

https://mfame.guru/novavax-on-the-verge-of-making-history/

Johnson & Johnson COVID Vaccine 99% Efficient in Single Dose

Shares of Johnson & Johnson rally after opioid fine

There is some good news on Johnson & Johnson’s coronavirus vaccine as trials show even one dose of their vaccine is effective against the virus, reports CNN.

What the trial result shows?
  • Early results from a Phase 1/2a clinical trial show it was well tolerated and even one dose appeared to produce a strong immune response in almost all of the 800 participants.
  • The trial included two age groups: 18- to 55-year-olds and 65 and older, and looked at the safety and side effects of two different doses.

https://mfame.guru/johnson-johnson-covid-vaccine-99-efficient-in-single-dose/

Pfizer Betting on Early COVID19 Vaccine Win, Protocol Shows

Pfizer Inc is betting that its coronavirus vaccine candidate will show clear evidence of effectiveness early in its clinical trial, according to the company and internal documents reviewed by Reuters that describe how the trial is being run.

Results By End of October?

In recent weeks, Pfizer has said it should know by the end of October whether the vaccine, developed together with Germany’s BioNTech SE, is safe and effective. If the vaccine is shown to work by then, Pfizer has said it would...

https://mfame.guru/pfizer-betting-on-early-covid19-vaccine-win-protocol-shows/

COVID19 Vaccine Developers Preparing ‘Vaccine Safety’ Pledge

According to an article published in the Wall Street Journal, several COVID-19 vaccine developers, including Pfizer, Johnson & Johnson and Moderna, plan to issue a public pledge not to seek government approval until their vaccine candidates are proven to be safe and effective.

Committed To Vaccine Safety

A draft of the joint statement, still being finalized by companies including Pfizer Inc., Johnson & Johnson and Moderna Inc. and reviewed by The Wall Street Journal, commits to making the safety...

https://mfame.guru/covid19-vaccine-developers-preparing-vaccine-safety-pledge/

+ More